Safety and Preliminary Efficacy of Vorinostat with R-EPOCH in High-risk HIV-associated Non-Hodgkin ’s Lymphoma (AMC-075)
Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in EBV+ or HHV-8+ tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). We performed a phase I trial of VOR given with R-based infusional EPOCH (n=12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 2, 2018 Category: Hematology Authors: Juan C. Ramos, Joseph A. Sparano, Michelle A. Rudek, Page C. Moore, Ethel Cesarman, Erin G. Reid, David Henry, Lee Ratner, David Aboulafia, Jeanette Y. Lee, Richard F. Ambinder, Ronald Mitsuyasu, Ariela Noy Tags: Original Study Source Type: research

Abnormal heavy/light chain ratio and matched pair suppression increase residual disease detection sensitivity in patients with multiple myeloma with deep responses
Heavy/light chain (HLC) assay can quantify both involved and uninvolved immunoglobulin pairs and is used to detect monoclonal proteins. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 2, 2018 Category: Hematology Authors: Kanji Miyazaki, Kenshi Suzuki Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 1, 2018 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 1, 2018 Category: Hematology Source Type: research

Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial
Hodgkin lymphoma is a curable disease with outcomes depending on initial prognostic factors and interim treatment response. Here, we conducted a phase II trial in advanced stage Hodgkin lymphoma to assess the feasibility and efficacy of a positron emission tomography-adapted strategy with early salvage for poor metabolic responders. We show that this strategy is feasible and leads to interesting results for the whole population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 21, 2018 Category: Hematology Authors: Sylvain Carras, Benjamin Dubois, Delphine Senecal, Jean-Philippe Jais, Michel Peoc'h, Philippe Quittet, Charles Foussard, Krimo Bouabdallah, Thomas Gastinne, Eric Jourdan, Laurence Sanhes, Marjan Ertault, Thierry Lamy, Lysiane Molina Tags: Original Study Source Type: research

Interim PET response adapted strategy in untreated advanced stage Hodgkin Lymphoma : results of GOELAMS LH 2007 phase 2 multicentric trial
Patients with advanced stage Hodgkin Lymphomas still present unsatisfactory outcomes. The GOELAMS group conducted a prospective multicentric trial (NCT00920153) for advanced stage HL to evaluate a PET adapted strategy. Patients received an intensive regimen (VABEM) in front-line and interim 18FFDG-PET evaluation after 2 courses (PET-2). Negative PET-2 patients received one additional course. Positive PET-2 patients underwent early salvage therapy followed by HDT/ASCT. Fifty-one patients were included. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 21, 2018 Category: Hematology Authors: S. Carras, B. Dubois, D. Senecal, J.P. Jais, M. Peoc ’h, P. Quittet, C. Foussard, K. Bouabdallah, T. Gastinne, Eric Jourdan, L. Sanhes, M. Ertault, T. Lamy, L. Molina Tags: Original Study Source Type: research

Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
This retrospective study analyzed the long-term outcome of 75 patients with t(4;14) multiple myeloma treated in a single center with frontline bortezomib-based treatment. Frontline autologous stem cell transplant following bortezomib-based induction was associated with better progression-free survival. These results further support the use of frontline autologous stem cell transplant, especially among patients with high-risk cytogenetics. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Henry Chan, Madeline Phillips, Manjula Maganti, Sophia Farooki, Giovanni Piza Rodriguez, Esther Masih-Khan, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti Tags: Original Study Source Type: research

Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction
This study analyzed the efficacy of pegfilgrastim in stem cell (PBSC) mobilization compared to filgrastim, exclusively after NA-based induction in a homogeneous group of MM patients. We analyzed 89 patients with MM treated at 2 transplant centers in Singapore who received NA-based induction chemotherapy, PBSC mobilization with vinorelbine/cyclophosphamide, high-dose melphalan conditioning and ASCT. This study demonstrates that a single dose of pegfilgrastim is comparable to filgrastim in terms of the timing and efficacy of PBSC harvest and could potentially spare the patient of 6 days of filgrastim injections. (Source: Cli...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Muhammad Bilal Abid, Sanjay De Mel, Muhammad Abbas Abid, Eng Soo Yap, Sathish Kumar Gopalakrishnan, Yunxin Chen, Yi Ching Yuen, Hung Chew Wong, Adeline Lin, Li Mei Poon, Liang Piu Koh, Wee Joo Chng, Lip Kun Tan Tags: Original Study Source Type: research

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
Despite the emerging paradigm favoring continuous therapy, we report that in routine clinical care, myeloma patients at first relapse frequently discontinue treatment before progression, resulting in duration of therapy that is significantly shorter than time to next therapy. We further describe the association between length of therapy in second line and improved overall survival in patients with relapsed/refractory multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Katarina Luptakova, Robert M. Rifkin, Linh Mai Tran, Aditya Raju, Eileen Farrelly, Stephen J. Noga, Marlo Blazer, Ajai Chari Tags: Original Study Source Type: research

Pegylated Filgrastim vs. Filgrastim for Stem Cell Mobilization in Multiple Myeloma after Novel Agent Induction
The current standard of care for transplant-eligible myeloma patients is novel agent-based induction followed by high-dose chemotherapy and autologous stem cell rescue. Chemo-mobilization of peripheral blood CD34+ stem cells (PBSC) with pegylated filgrastim (pegfilgrastim), a sustained-duration formulation of filgrastim, has been used as an alternative to filgrastim in several studies involving heterogeneous cohorts of lymphoma and multiple myeloma (MM) patients and shown to be equivalent in PBSC yield and cost-effectiveness. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Muhammad Bilal Abid, SanjayDe Mel, Muhammad Abbas Abid, Eng Soo Yap, Sathish Kumar Gopalakrishnan, Yunxin Chen, Yi Ching Yuen, Hung Chew Wong, Adeline Lin, Michelle Poon Limei, Liang Piu Koh, Wee Joo Chng, Lip Kun Tan Tags: Original Study Source Type: research

Single center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation
Multiple myeloma (MM) is a malignant plasma cell condition with variable long-term outcomes. Depending on the patients ’ risk factors, long-term overall survival can range from under 2 years to more than 10 years [1, 2]. One of the most important prognostic factors in this condition is disease cytogenetics, which are now commonly assessed using fluorescent in-situ hybridization (FISH) [1-3]. Amongst all of the cyt ogenetic abnormalities detected by FISH that are deemed as high-risk, translocation of the fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET) on chromosome 4 with the IgH ge...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 5, 2018 Category: Hematology Authors: Henry Chan, Madeline Phillips, Manjula Maganti, Sophia Farooki, Giovanni Piza Rodriguez, Esther Masih-Khan, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti Tags: Original Study Source Type: research

A Comparison of the Efficacy of Immunomodulatory-Containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
A systematic review and network meta-analysis were conducted to compare the clinical efficacy of immunomodulatory drug –containing regimens in patients with RRMM. Daratumumab plus lenalidomide and dexamethasone had a significant advantage in improving progression-free survival in patients compared to other immunomodulatory-containing regimens. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 4, 2018 Category: Hematology Authors: Meletios Athanasios Dimopoulos, Jonathan L. Kaufman, Darrell White, Gordon Cook, Maria Rizzo, Yingxin Xu, Kyle Fahrbach, Maren Gaudig, Mary Slavcev, Lindsay Dearden, Annette Lam Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma
Until recently, advances in classical Hodgkin lymphoma (HL) treatment primarily consisted of minor modifications of highly effective decades-old chemotherapy and radiation approaches. In early stage disease, excellent outcomes have been reported with fewer cycles of chemotherapy, lower doses and smaller radiation fields, and in some circumstances radiation elimination. In advanced stage disease, maintaining dose intensity of standard chemotherapy regimens has resulted in modest improvements in outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 4, 2018 Category: Hematology Authors: Marcus P. Watkins, Michelle A. Fanale, Nancy L. Bartlett Tags: Review Article Source Type: research

HIV-Related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab
We present a case of a patient with well-controlled human immunodeficiency virus (HIV) infection and refractory classical Hodgkin lymphoma (HL) treated with nivolumab as fifth-line treatment, who achieved complete response (CR) by positron emission tomography –computed tomography (PET/CT). To our knowledge, this is the second case report of a patient exhibiting nivolumab’s response, and first reported CR in the setting of HIV-associated HL (HIV-HL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 3, 2018 Category: Hematology Authors: Elaine Chang, Gustavo Rivero, Niraj R. Patel, Elizabeth Y. Chiao, Syeling Lai, Kelash Bajaj, John E. Mbue, Sarvari V. Yellapragada Tags: Case Report Source Type: research

Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom
A Markov model was used to assess the cost-effectiveness of ibrutinib compared with obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results showed ibrutinib not to be cost-effective. However, additional analyses showed ibrutinib to be significantly cost-effective compared with the current mode of care in which ibrutinib is administered as the second-line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Richa Sinha, William Ken Redekop Tags: Original Study Source Type: research

Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging
The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved according to positron emission tomography-computed tomography imaging after chemotherapy. In this series, low-dose (approximately 20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Long-term toxicity was similar between chemotherapy and combined modality therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Erin J. Song, Jordan Torok, Yuan Wu, Junzo Chino, Leonard R. Prosnitz, Anne W. Beaven, Chris R. Kelsey Tags: Original Study Source Type: research

Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma in Complete Metabolic Response by PET-CT or Gallium
The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved by PET-CT after chemotherapy. In this series, low-dose ( ∼20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD. Long-term toxicity was similar between chemotherapy and combined modality therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Erin J. Song, Jordan Torok, Yuan Wu, Junzo Chino, Leonard R. Prosnitz, Anne W. Beaven, Chris R. Kelsey Tags: Original Study Source Type: research

Mechanisms of Hypercalcemia in non-Hodgkin Lymphoma and Associated Outcomes: a Retrospective Review
The etiology of hypercalcemia in non-Hodgkin lymphoma (NHL) is most often attributed to either elevated serum levels of 1,25-dihydroxycholecalciferol (calcitriol) or parathyroid-related protein (PTHrP). In a single center retrospective review we evaluated the incidence of and outcomes associated with hypercalcemia in NHL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Rory M. Shallis, Rachel S. Rome, John L. Reagan Tags: Original Study Source Type: research

Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom
A Markov model was used to assess the cost-effectiveness of ibrutinib compared to obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results demonstrated ibrutinib not to be cost-effective. However, additional analyses demonstrated ibrutinib to be significantly cost-effective when compared to the current mode of care in which ibrutinib is administered as the second-line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Richa Sinha, William Ken Redekop Tags: Original Study Source Type: research

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
HRQoL was evaluated among RBC-TD patients with lower-risk non-del(5q) MDS treated with lenalidomide (n = 160) or placebo (n = 79) in the phase 3 MDS-005 study. Lenalidomide did not worsen HRQoL; response to lenalidomide was associated with significant HRQoL improvement. Lenalidomide represents a treatment option for patients with lower-risk non-del(5q) MDS who are ineligible for or refractory to ESAs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 29, 2017 Category: Hematology Authors: Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Uwe Platzbecker, Rena Buckstein, C.L. Beach, Shien Guo, Arman Altincatal, Chengqing Wu, Pierre Fenaux Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 23, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 23, 2017 Category: Hematology Source Type: research

Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation
We have read with great interest the paper by Trifilio and colleagues,1 entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.” The authors illustrated the result of a retrospective comparative clinical trial of an olanzapine-cont aining regimen versus an aprepitant- or fosaprepitant-containing regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 22, 2017 Category: Hematology Authors: Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese, Rome Transplant Network Tags: Letter to the Editor Source Type: research

Consolidative Radiotherapy to Residual Masses After Chemotherapy is Associated With Improved Outcome in Diffuse Large B-cell Lymphoma. a Retrospective, Population-Based Study
The role of radiotherapy (RT) in Diffuse Large B-cell lymphomas with advanced disease is unclear. In this retrospective study, two cooperating university hospitals in Western Norway had different practices in use of RT, but similar patient characteristics and chemotherapy. RT to a residual mass after chemotherapy, in low-intermediate risk groups with advanced disease, was associated with improved cancer-specific and overall survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 22, 2017 Category: Hematology Authors: Øystein Fluge, Bård Mannsåker, Anders Torp, Ingvil Mjaaland, Lars Helgeland, Jan Klos, Olav Mella, Sigbjørn Berentsen, Peter Meyer Tags: Original Study Source Type: research

Should we Use Cell of Origin and Dual-Protein Expression in Treating DLBCL?
Treatment outcomes in diffuse large B-cell lymphoma (DLBCL) following standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy is highly variable and dependent on a number of clinical, biologic, and genetic features. The identification of molecular heterogeneity via gene expression profiling dichotomizes patients based on the cell of origin (COO) model into germinal center B-cell like (GCB) and activated B-cell like (ABC) subsets, with ABC-DLBCL having a worse outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 22, 2017 Category: Hematology Authors: Peter A. Riedell, Sonali Smith Tags: Review Article Source Type: research

Chemotherapy Induced Nausea and Vomiting Prophylaxis in High-Dose Melphalan and Autologous Stem Cell Transplantation
We have read with great interest the paper by Trifilio S. and colleagues1, entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study”. The authors illustrated the result of a retrospective comparative clinical trial of olanzapine-contain ing regimen versus aprepitant or fosaprepitant-containing regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT) with h...
Source: Clinical Lymphoma, Myeloma and Leukemia - December 22, 2017 Category: Hematology Authors: Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese Tags: Letter to the Editor Source Type: research

Analysis of Real-World Data on Postremission Therapy for Acute Myeloid Leukemia with Intermediate Risk Cytogenetics in First Complete Remission
Curative treatment of acute myeloid leukemia (AML) is based on one or two cycles of remission induction chemotherapy followed by consolidation chemotherapy or allogeneic hematopoietic cell transplantation (HCT) in those patients who enter complete remission (CR). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 6, 2017 Category: Hematology Authors: Jan Vydra, Cyril Šálek, Jiří Schwarz, Pavel Žák, Jan Novák, Veronika Petečuková, Pavla Pecherková, Jiří Mayer, Petr Cetkovský, Zdeněk Ráčil Tags: Original Study Source Type: research

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence in Situ Hybridization/Cytogenetics: A Real-World Clinical Experience in the Connect CLL Registry
Prognostic genetic testing can guide treatment decisions and predict outcomes for patients with chronic lymphocytic leukemia (CLL). Among 1,494 patients with CLL treated in the community setting, prognostic genetic testing was infrequently performed and outcomes were inferior for patients with unfavorable-risk disease. This highlights the importance of prognostic testing for patients with CLL to guide treatment and improve outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 5, 2017 Category: Hematology Authors: Anthony Mato, Chadi Nabhan, Neil E. Kay, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Shriya Bhushan, Kristen Sullivan, E. Dawn Flick, Jeff P. Sharman Tags: Original Study Source Type: research

Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER –Medicare Cohort
We used the Surveillance, Epidemiology, and End Results (SEER) –Medicare-linked database to characterize the patterns of presentation, treatment, and survival in older diffuse large B-cell lymphoma (DLBCL) patients with concomitant autoimmune disease. DLBCL patients with autoimmune disease were more likely to be female but otherwise did not differ significant ly from other DLBCL patients in demographic data, treatment, or clinical outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 1, 2017 Category: Hematology Authors: Jean L. Koff, Ashish Rai, Christopher R. Flowers Tags: Original Study Source Type: research

Characterizing autoimmune disease-associated diffuse large B cell lymphoma in a SEER-Medicare cohort
We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to characterize patterns of presentation, treatment, and survival in older DLBCL patients with concomitant autoimmune disease. DLBCL patients with autoimmune disease were more likely to be female, but otherwise did not differ significantly from other DLBCL patients in demographics, treatments and clinical outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - December 1, 2017 Category: Hematology Authors: Jean L. Koff, Ashish Rai, Christopher R. Flowers Tags: Original Study Source Type: research

SOHO state-of-the-art update and next questions: MPN
The discovery of the activating JAK2V617F mutation in 2005 in the majority of patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in CALR in 2013, thus providing additional mechanistic explanations for the universal activation of Janus kinase-signal transducer and activator of transcription (JAK-STAT) observed in these conditions, and the success of the JAK1/2 inhibitor ruxolitinib, which first received regulatory approval in 2011. (Source: ...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 30, 2017 Category: Hematology Authors: Prithviraj Bose, Jason Gotlib, Claire N. Harrison, Srdan Verstovsek Tags: Review Article Source Type: research

Danazol as First-Line Therapy for Myelodysplastic Syndrome
At present, no standard therapy is available for most patients with myelodysplastic syndrome. In this retrospective study, we analyze data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option because of its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 29, 2017 Category: Hematology Authors: Perla Roc ío Colunga-Pedraza, Julia Esther Colunga-Pedraza, María Alejandra Garza-Ledezma, Jose Carlos Jaime-Pérez, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, Erick Joel Rendón-Ramírez, Yadith Karina López-García, Rosa Elena Tags: Original Study Source Type: research

Danazol as first-line therapy for myelodysplastic syndromes
At present, no standard therapy is available for most patients with myelodysplastic syndromes. In this retrospective study, we analyse data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option due to its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 29, 2017 Category: Hematology Authors: Perla Roc ío Colunga-Pedraza, Julia Esther Colunga-Pedraza, María Alejandra Garza-Ledezma, Jose Carlos Jaime-Pérez, Olga Graciela Cantú-Rodríguez, César Homero Gutiérrez-Aguirre, Erick Joel Rendón-Ramírez, Yadith Karina López-García, Rosa Elena Tags: Original Study Source Type: research

Considerations for Successful Treatment-Free Remission in Chronic Myeloid Leukemia
BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with chronic myeloid leukemia, and current studies are investigating whether some patients may be able to suspend therapy yet maintain response in a state known as “treatment-free remission” (TFR). Results from ongoing studies suggest that ≈ 40% to 60% of patients in sustained (generally ≥ 2 years) deep molecular response (defined as a 4-log or deeper reduction in BCR-ABL1 transcripts, depending on the study) who attempt TFR may successfully remain off treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 29, 2017 Category: Hematology Authors: Stuart L. Goldberg, Michael Savona, Michael J. Mauro Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 22, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 22, 2017 Category: Hematology Source Type: research

A Tribute to Dr Lillian M. Fuller
On September 29, 2017, Dr Lillian Mary Fuller passed away peacefully at the age of 94, after a lengthy period of physical decline. She remained mentally sharp until the end. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 22, 2017 Category: Hematology Authors: Peter McLaughlin, Moshe H. Maor Tags: Tribute Source Type: research

How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT
Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and ∼90% of patients who present with early-stage (stage I-II) disease and 70% of patients who present with late-stage disease will be cured with standard frontline treatment. For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy, fo llowed by autologous transplantation (autoSCT). Although this approach will cure a significant proportion of patients, upto 50% of patients will experience disease progression after autoSCT, and this population has historically had a very poor prognosis. (Sou...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Matthew Mei, Robert Chen Tags: Review Source Type: research

Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma
Several studies have suggested that hematopoietic stem cell transplantation (HSCT) might provide a cure for primary cutaneous aggressive epidermotropic cytotoxic CD8-positive T-cell lymphoma (CD8+ PCAETL). We summarize published literature on this disease and present outcomes of 8 patients with CD8+ PCAETL treated at our institution. In our experience, allogeneic HSCT and the novel agents brentuximab and pralatrexate show substantial activity against this disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Benoit M. Cyrenne, Juliet Fraser Gibson, Antonio Subtil, Michael Girardi, Iris Isufi, Stuart Seropian, Francine Foss Tags: Original Study Source Type: research

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP
The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. We analyzed 45 patients with FLG3 treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). R-CHOP showed to be an effective first-line treatment for these patients, and provided extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L. Jeffrey Medeiros, Michael J. Overman, Jorge E. Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B. Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S. Neelapu, Luis Tags: Original Study Source Type: research

Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)
The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. This is a case series of 45 patients with FLG3 treated with frontline R-CHOP and observed for an extended time interval. The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph node sites more than 4 and presence of B symptoms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L. Jeffrey Medeiros, Michael J. Overman, Jorge E. Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B. Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S. Neelapu, Luis Source Type: research

Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 Positive T-Cell Lymphoma
Several studies have suggested that hematopoietic stem cell transplant (HSCT) may provide a cure for Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive T-Cell Lymphoma (CD8+ PCAETL). We summarize published literature on this disease and present outcomes of 8 patients with CD8+ PCAETL treated at our institution. In our experience, allogeneic HSCT and the novel agents brentuximab and pralatrexate demonstrate substantial activity against this disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Benoit M. Cyrenne, Juliet Fraser Gibson, Antonio Subtil, Michael Girardi, Iris Isufi, Stuart Seropian, Francine Foss Source Type: research

How to approach a Hodgkin lymphoma patient who relapses after autologous SCT: Allogeneic SCT
Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and approximately 90% of patients who present with early stage (I-II) disease (1) and 70% of patients who present with late-stage disease will be cured with standard frontline treatment(2). For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy followed by autologous transplant (autoSCT). While this approach will cure a significant proportion of patients, up to 50% of patients will experience disease progression after autoSCT(3), and this population has historically had a very poor prognosis. (Sour...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Matthew Mei, Robert Chen Source Type: research

Efficacy of standard dose R-CHOP alternating with R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single institution experience
In a retrospective study of 87 patients with mantle cell lymphoma treated with 3 different induction regimens, we show that a modification of the Nordic regimen in which a standard, rather than dose-intense, R-CHOP alternating with high dose cytarabine is a highly effective pre-autologous hematopoietic cell transplantation therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Yazeed Sawalha, Brian T. Hill, Lisa A. Rybicki, Danyu Sun, Robert M. Dean, Deepa Jagadeesh, Betty K. Hamilton, Aaron T. Gerds, Ronald M. Sobecks, Steven Andresen, Hien K. Liu, Navneet S. Majhail, Brad Pohlman, Matt E. Kalaycio, Brian J. Bolwell, Mitchell Source Type: research

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma
The present phase II study has demonstrated that augmenting neutrophil function by the addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin lymphoma while retaining the excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population for whom therapeutic options are limited owing to poor tolerance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 6, 2017 Category: Hematology Authors: Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A. Bhat, Myron S. Czuczman, Kelvin P. Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J. Hernandez-Ilizaliturri Tags: Original Study Source Type: research

A Phase II Trial of Rituximab in Combination with Pegfilgrastim in Patients with Indolent B-Cell Non-Hodgkin ’s Lymphoma
This phase 2 study demonstrates that augmenting neutrophil function by addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin ’s lymphomas (B-NHL) while retaining its excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population where therapeutic options are limited due to poor tolerance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 6, 2017 Category: Hematology Authors: Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A. Bhat, Myron S. Czuczman, Kelvin P. Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J. Hernandez-Ilizaliturri Source Type: research

VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study
VcR-CVAD with maintenance rituximab is an intermediate-intensity regimen for older and younger mantle cell lymphoma (MCL) patients. Thirty patients were treated, with primary end point of response and secondary endpoints of progression-free and overall survival. After a median follow-up of 7.8 years, no relapses were observed beyond 6 years. VcR-CVAD has long-term outcomes comparable with more intensive chemotherapy regimens. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 3, 2017 Category: Hematology Authors: J.E. Chang, L.L. Carmichael, K. Kim, C. Peterson, D.T. Yang, A.M. Traynor, J.E. Werndli, M.S. Huie, T.A. McFarland, M. Volk, J. Blank, N.S. Callander, W.L. Longo, Kahl Source Type: research

Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience
The purpose of the present study was to understand the effect of early relapse (ER) on the overall survival of myeloma patients. We analyzed the outcomes of 257 patients who had received novel agent-based induction therapy and undergone single autologous stem cell therapy at our center from 2010 to 2016. We have concluded that ER, high-risk cytogenetics, and lactate dehydrogenase> 350 UI/L are significant prognosticators for poor patient outcome in those with multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2017 Category: Hematology Authors: Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J. Bahlis, Victor H. Jimenez-Zepeda Tags: Original Study Source Type: research

Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma
Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of patients demonstrating an overall response rate of 42%. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2017 Category: Hematology Authors: Megan M. Saraceni, Emma Scott, Richard T. Maziarz, Matthew B. Siegel, Solange Bassale, Susie Jiing, Eva Medvedova Tags: Original Study Source Type: research

Early relapse for Multiple Myeloma patients undergoing single auto-SCT: A single center experience
The purpose of this study was to understand the impact of early relapse (ER) on overall survival of myeloma patients. We analyzed the outcomes of 257 patients who received novel agent based inductions and underwent single auto-SCT at our center between 2010 and 2016. We conclude that ER, high-risk cytogenetics, and LDH>350 UI/L are significant prognosticators for poor patient outcome in multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2017 Category: Hematology Authors: Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J. Bahlis, Victor H. Jimenez-Zepeda Tags: Original Study Source Type: research